Panobinostat (LBH589)
by Jessica Langholtz
Updated: Dec 3, 2009
Updated: Dec 3, 2009
| Brand Name: | |
| Generic Name: | panobinostat |
| Code Name: | LBH589 |
| Company: | Novartis |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Panobinostat (news articles), which is a potent histone deacetylase (HDAC) inhibitor, selectively targets tumor cells for cell death. In Phase 1 trials, panobinostat was highly active as a single agent treatment for several types of cancer, including multiple myeloma, Hodgkin’s lymphoma, acute myeloid leukemia, and prostate cancer. Additional clinical trials are currently underway to examine the efficacy and safety profile of panobinostat.
Clinical Trials:
For a list of clinical trials studying panobinostat for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official Web site for panobinostat: http://www.novartisoncology.com/research-innovation/pipeline/panobinostat.jsp
Related Articles:
- Panobinostat Combinations Show Therapeutic Benefit In Advanced Multiple Myeloma (ASCO 2010)
- Panobinostat Combination May Be Effective In Relapsed And Velcade-Refractory Multiple Myeloma (ASH 2011)
- IMW 2009 – Elotuzumab And Panobinostat Clinical Trials With Velcade
- Beacon NewsFlashes – January 29, 2009
- Beacon NewsFlashes – December 10, 2010
Leave a comment